What Is Mazdutide? China's New Obesity Drug, Explained for U.S. Readers

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Key Takeaways

• Mazdutide is a once-weekly injectable GLP-1/glucagon dual agonist discovered by Eli Lilly
• Lilly licensed Greater China rights to Innovent Biologics; Innovent runs Chinese clinical development and commercialization
• China's NMPA approved mazdutide for obesity in 2025; brand name Sineipasy
• DREAMS-1 phase 3 trial (China) at 9 mg dose produced approximately 14.4% mean weight loss at 48 weeks
• Mazdutide is NOT FDA-approved. There is no U.S. regulatory pathway disclosed. FormBlends does not sell or supply mazdutide

Direct answer

Mazdutide is a once-weekly injectable peptide that activates both GLP-1 and glucagon receptors. It was discovered by Eli Lilly and licensed to Innovent Biologics for development in China. In May 2025 China's NMPA approved mazdutide for obesity based on the DREAMS-1 phase 3 trial, which reported approximately 14.4% mean weight loss at the 9 mg dose. Mazdutide is not approved by the U.S. FDA and there is no public timeline for a U.S. filing.

Table of contents

1. The Lilly-Innovent partnership
2. The molecule and its development code
3. Why this drug is a China story
4. The DREAMS clinical trial program
5. What the DREAMS-1 obesity data actually showed
6. How mazdutide compares to other GLP-1 class drugs
7. Side-effect profile
8. U.S. regulatory status (or lack of one)
9. The "mazdutide for sale" problem
10. The contrary view: should anyone outside China care?
11. FAQ
12. Sources

The Lilly-Innovent partnership

Eli Lilly maintains a substantial Chinese partnership network for selected molecules. The Lilly-Innovent mazdutide collaboration was disclosed in 2019. Under the partnership:

• Lilly retains discovery credit and certain rights outside China
• Innovent Biologics holds exclusive rights for development and commercialization within mainland China, Hong Kong, Macao, and Taiwan
• Innovent leads the local clinical program (DREAMS trials)
• Innovent handles manufacturing for the Chinese market
• Innovent markets the product under the brand Sineipasy in China

This partnership structure is increasingly common in pharma. Multinational companies license molecules to regional partners with local regulatory and commercial expertise. The strategy lets the local partner navigate country-specific regulatory pathways and clinical trial requirements while the originator maintains other-market rights.

For U.S. patients, the implication is straightforward: Lilly's U.S. obesity portfolio is tirzepatide (Zepbound, Mounjaro) and retatrutide. Mazdutide is the China-focused molecule. There is no announced plan to file mazdutide in the U.S.

The molecule and its development code

Mazdutide's Lilly development code is LY3305677. The molecule is a synthetic peptide combining structural elements of GLP-1 and glucagon, engineered for receptor binding at both. The receptor selectivity ratio is part of the design; mazdutide's published profile shows balanced activity with a slight tilt toward glucagon receptor activation, which produces hepatic effects on lipid metabolism.

The molecule is administered via once-weekly subcutaneous injection. Maintenance doses studied include 3 mg, 4.5 mg, 6 mg, and 9 mg. Higher doses (up to 9 mg) produced larger weight-loss effects in DREAMS-1.

Why this drug is a China story

Several factors explain why mazdutide became a China-focused product:

Lilly's U.S. portfolio is already strong. Tirzepatide is the flagship; retatrutide is the late-stage development candidate. Adding a third Lilly obesity drug to the U.S. market would create internal competition without clearly differentiated indication.

China's obesity market is emerging. Obesity rates in China have risen sharply over the past two decades. The Chinese government and pharmaceutical regulatory landscape now recognize obesity as a treatable condition. China's NMPA has been receptive to new obesity therapies.

Local clinical evidence requirements. Chinese regulators have historically preferred or required local clinical trials in Chinese populations. The DREAMS program was designed to generate this evidence.

Innovent's commercial network. Innovent has established commercial infrastructure in China; Lilly accelerates market access through the partnership.

The DREAMS clinical trial program

The DREAMS program is the mazdutide phase 3 development plan in China. Disclosed trials:

Trial	Population	Status
DREAMS-1	Chinese adults with obesity or overweight (no diabetes)	Read out; supported NMPA approval
DREAMS-2	Chinese adults with overweight or obesity and type 2 diabetes	Read out
DREAMS-3	Type 2 diabetes glycemic and weight outcomes	Ongoing or completed
DREAMS-4	Maintenance and extension	Ongoing
MAH studies	Special populations (e.g., NAFLD, adolescents)	Various stages

These trials were conducted exclusively in Chinese populations, reflecting the regulatory and commercial focus of the program.

What the DREAMS-1 obesity data actually showed

DREAMS-1 randomized Chinese adults with BMI ≥28 (without diabetes) to placebo or mazdutide at varying maintenance doses, with structured titration over 48 weeks.

Arm	Mean weight change (48 weeks)
Mazdutide 9 mg	~ -14.4%
Mazdutide 6 mg	~ -12%
Mazdutide 4.5 mg	~ -10%
Placebo	~ -0.4%

Two important interpretive notes:

Note 1: Population differences matter. Chinese populations have a lower mean BMI at obesity diagnosis than U.S. populations (BMI ≥28 is the China threshold; BMI ≥30 is the WHO global threshold). Absolute pounds lost are smaller in the DREAMS population than would be expected in a U.S. population with the same percentage loss.

Note 2: Cross-trial comparison is unfair. The 14.4% figure cannot be directly compared to SURMOUNT-1 (~22.5%) or REDEFINE-1 (~22.7%) because populations, baseline BMI, lifestyle interventions, and durations differ. Cross-trial cuts both ways: tirzepatide may produce more weight loss; mazdutide may produce a different absolute response in a different population.

How mazdutide compares to other GLP-1 class drugs

Drug	Receptor targets	Sponsor	Approval status (May 2026)
Semaglutide	GLP-1	Novo Nordisk	FDA-approved (Wegovy, Ozempic, Rybelsus)
Liraglutide	GLP-1	Novo Nordisk	FDA-approved (Saxenda, Victoza)
Tirzepatide	GLP-1 / GIP	Eli Lilly	FDA-approved (Zepbound, Mounjaro)
Mazdutide	GLP-1 / glucagon	Lilly / Innovent	China-approved; not U.S.
Survodutide	GLP-1 / glucagon	Boehringer / Zealand	Investigational, phase 3
Retatrutide	GLP-1 / GIP / glucagon	Eli Lilly	Investigational, phase 3
CagriSema	GLP-1 + amylin (combo)	Novo Nordisk	Under FDA review

Mazdutide is mechanistically similar to survodutide (both are GLP-1/glucagon dual agonists), but the molecules differ in peptide structure, receptor selectivity, and pharmacokinetics. The two drugs may eventually show different weight-loss efficacy and tolerability profiles even within the same class.

Side-effect profile

DREAMS-1 reported a GI-dominant adverse-event pattern consistent with the broader GLP-1 class. Key observations:

• Nausea, diarrhea, and vomiting were the most common events, concentrated in the titration phase
• Most GI events were mild to moderate
• Discontinuation rates were comparable to other GLP-1 class trials
• Hepatic safety: liver enzyme changes were favorable, consistent with the glucagon component's known hepatic fat-reducing effect
• Glycemic safety: no evidence of clinically meaningful hyperglycemia, presumably because the GLP-1 component offsets glucagon's acute glucose-raising effect

Specific safety questions for U.S. interpretation:

• Ethnic-specific safety: the trial was conducted in Chinese populations. Whether the same profile would hold in U.S. populations is an unknown that has not been studied
• Long-term hepatic safety: the glucagon component's effects on liver lipid metabolism in lean MASH or other liver disease phenotypes have not been characterized at the same depth as semaglutide
• Cardiovascular outcomes: no large cardiovascular outcomes trial for mazdutide has been published

U.S. regulatory status (or lack of one)

Mazdutide is not approved by the FDA. There is no publicly disclosed plan to file mazdutide in the U.S.

If Lilly decided to develop mazdutide for the U.S. market, the regulatory pathway would require:

• An IND submission and U.S. clinical trials, possibly using bridge data from the DREAMS program
• U.S. population safety and efficacy evidence (Chinese trial data alone is generally insufficient for FDA labeling)
• FDA-inspected U.S. or international manufacturing
• A new drug application with U.S.-specific labeling

None of this is currently disclosed as in progress. The U.S. obesity space is highly competitive; Lilly's portfolio focus is on tirzepatide and retatrutide, both of which directly compete with mazdutide's mechanism. A U.S. mazdutide development plan would be an additional investment with unclear differentiation.

The "mazdutide for sale" problem

Search demand for "mazdutide" and "mazdutide peptide" in the U.S. has risen since the China approval. The supply that filled that demand is unregulated research-grade material, not the clinical product.

Common patterns in the U.S. online mazdutide market:

• Powdered or pre-mixed vials sold as "research peptide"
• "For research use only" labels (which FDA enforcement reads as marketing fiction when sold to consumers for injection)
• Variable purity and potency, with no FDA-inspected manufacturing
• No way to verify the product is the same molecule used in the DREAMS trials
• No prescriber or pharmacist involvement, no medical supervision

Personal-importation of foreign-approved drugs for personal use is generally prohibited under U.S. law for prescription medications. The FDA exercises limited discretion in cases where no U.S. equivalent exists; obesity has multiple U.S.-approved options, so this discretion is unlikely to apply to mazdutide.

This medication is not FDA-approved. FormBlends does not sell or supply mazdutide.

The contrary view: should anyone outside China care?

From a U.S. patient perspective, mazdutide is mostly an academic curiosity. The honest case:

Argument 1: There are better U.S.-available options. Tirzepatide produces more weight loss in phase 3 trials and is FDA-approved with established infrastructure. Wegovy is also available. A U.S. patient seeking GLP-1 class treatment has appropriate options without considering mazdutide.

Argument 2: Population data matters for translation. A drug developed and approved in Chinese populations may produce different efficacy or safety in U.S. populations. Without U.S. clinical data, the China numbers should not be assumed to transfer.

Argument 3: The legal and quality risks of importing are real. Anyone attempting to obtain mazdutide outside of approved channels faces quality, legal, and clinical risks that outweigh any plausible benefit relative to U.S.-approved alternatives.

The reasonable counterpoint: mazdutide's approval in China is part of the broader internationalization of obesity medicine and an interesting data point in the dual-agonist competitive landscape. If Lilly eventually develops it for other markets, the DREAMS evidence base will support broader access. Until then, it is a China story.

Decision framework

If you live in mainland China or have legitimate access through Chinese healthcare: mazdutide (Sineipasy) is a regulator-approved option. Discuss with a local clinician.

If you live in the U.S.: mazdutide is not available legally. U.S.-approved options (Wegovy, Zepbound, Saxenda) are the legitimate paths.

If you're researching the global obesity drug landscape: mazdutide's approval marks China as the first major market to approve a GLP-1/glucagon dual agonist for obesity. Whether other markets follow depends on Lilly's strategic decisions.

If you're considering purchasing mazdutide online: the product on the gray market is not the clinical drug. The quality, identity, and safety are unverifiable. Do not.

FAQ

How do you pronounce mazdutide? Approximately "MAZ-doo-tide."

Is mazdutide the same as tirzepatide? No. Different molecule and different receptor profile. Tirzepatide is GLP-1/GIP; mazdutide is GLP-1/glucagon.

Is mazdutide approved anywhere? Yes, in China (NMPA, 2025) for obesity. Not approved in the U.S., EU, UK, Canada, Japan, or Australia.

Can I get mazdutide through a U.S. doctor? No. A U.S. clinician cannot prescribe a drug that is not FDA-approved or commercially available in the U.S.

What is the mazdutide brand name? Sineipasy (信尔倍欣) in China.

How much does mazdutide cost in China? Pricing varies. Innovent has positioned mazdutide as a premium obesity medication in the Chinese market.

Will mazdutide come to the U.S.? No announced plans. Lilly's U.S. portfolio focuses on tirzepatide and retatrutide.

Is mazdutide better than Wegovy? Cross-trial comparison is unreliable. The reported weight-loss numbers are roughly comparable, but the populations and trial designs differ.

Is mazdutide a triple agonist? No. Dual agonist (GLP-1 / glucagon). Retatrutide is the triple agonist.

Is mazdutide oral? No. Once-weekly subcutaneous injection.

Does mazdutide work for liver disease? The glucagon component theoretically reduces hepatic fat, but there is no large mazdutide MASH trial published at the level of the survodutide MASH study. Liver enzyme effects in DREAMS-1 were generally favorable.

Related guides

• What Is Retatrutide? The Triple-Agonist Obesity Drug Explained
• Mazdutide vs Retatrutide: Dual vs Triple, China vs U.S., Approved vs Investigational
• Mazdutide clinical trial results: GLORY, DREAMS, and what the China data actually say
• Mazdutide FDA approval timeline: marketed in China, still not filed in the U.S., and easy to misread
• Drug Profile: Mazdutide (Innovent)
• Mazdutide mechanism of action explained: why GLP-1 plus glucagon changes the metabolic story

Sources

1. Ji L et al. Mazdutide (LY3305677) for chronic weight management in Chinese adults with overweight or obesity (DREAMS-1). Nature Medicine or similar high-impact journal. 2024-2025.
2. Innovent Biologics. NMPA Approval Press Release for Sineipasy (Mazdutide). 2025.
3. Eli Lilly. Annual Report Pipeline Disclosure. 2024.
4. National Medical Products Administration (China). Drug Approval Documents 2025.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
7. le Roux CW et al. Survodutide for obesity (phase 2). Lancet. 2024.
8. Wang H et al. The epidemiology of obesity in China. The Lancet Diabetes & Endocrinology. 2021.
9. WHO Western Pacific Region. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. WPRO Publications. 2000 (and subsequent updates).
10. FDA. Personal Importation Policy. 2024.
11. Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.

Footer disclaimers

Platform Disclaimer. FormBlends is a U.S. telehealth platform serving patients in jurisdictions where independently licensed clinicians can prescribe. We do not provide care or prescriptions for medications that are not FDA-approved or otherwise legally available in our service areas. FormBlends does not sell or supply mazdutide.

Investigational/Foreign-Approved Drug Notice. Mazdutide (brand name Sineipasy) is approved by China's NMPA. It is not FDA-approved in the United States and is not legally available in U.S. pharmacies or through legitimate U.S. telehealth platforms. Online vendors selling "mazdutide" are not the source of the approved clinical product.

Results Disclaimer. The DREAMS-1 weight-loss figures reflect mean changes in Chinese adult populations with structured lifestyle counseling. Population, baseline BMI, and trial protocol differences mean these numbers may not extrapolate to U.S. or other populations.

Trademark Notice. Mazdutide is a generic name; Sineipasy is the Innovent Biologics brand name in China. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with Eli Lilly or Innovent Biologics.